You are here: Industry Insights > Agenus

News List

Agenus Commences Phase 1 Trial with AGEN1223 americanpharmaceuticalreview
January 09, 2020
Agenus announced the dosing of the first patient with AGEN1223. AGEN1223 is a novel bi-specific antibody discovered by Agenus and designed to deplete regulatory T cells in the tumor microenvironment.
Agenus Commences Trial of Next-Gen CTLA-4 with PD-1 Antibody americanpharmaceuticalreview
December 20, 2019
Agenus announced the first patient dosed with AGEN1181, an anti-CTLA-4 antibody, in combination with balstilimab, Agenus' PD-1 inhibitor.
Agenus, Gilead Milestone Triggers $7.5M Payment contractpharma
August 09, 2019
FDA acceptance of IND filing for AGEN237 represents the second milestone in Gilead partnership achieved in 2019.
Gilead inks $1.8 bn deal with immuno-oncology biotech Agenus pharmafile
December 24, 2018
California-based firm Gilead Sciences and Massachusetts-based immuno-oncology biotech Agenus have announced that they have entered into a partnership focused on the development
Gilead & Agenus form $1.8bn partnership pharmatimes
December 24, 2018
Gilead Sciences and Agenus have announced a partnership to focus on the development and commercialisation of up to five novel immuno-oncology therapies.
Gilead and Agenus sign cancer drug development deal pharmaceutical-technology
December 24, 2018
Gilead Sciences has partnered with US-based biotechnology company Agenus for the development and commercialisation of up to five immuno-oncology (I-O) treatments......
Agenus Receives Second Milestone from Merck contractpharma
August 21, 2018
Agenus Inc. announced today that Merck initiated a Phase I clinical trial of an undisclosed antibody candidate discovered by Agenus, under the two companies license and research collaboration.

Previous page 1 2 Next page